News and Announcements
Universal Biosensors (ASX:UBI) CEO Interview
- Published July 08, 2015 4:08PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Universal Biosensors (ASX:UBI) is a specialist medical diagnostics company developing and manufacturing test systems for point-of-care (POC) medical professionals and home use.
UBI’s core technology is a disposable, multi-layer test strip, which uses its proprietary electrochemical sensor to rapidly and accurately measure biomarkers in the blood.
The first product developed by UBI with LifeScan (a Johnson & Johnson company) is a blood glucose measurement device and is on the market and generating revenues for UBI. The second product developed by UBI in collaboration with Siemens Healthcare has also been launched.
The global point-of-care diagnostics market is estimated to be worth nearly US$17 billion a year and growing.
Please listen to Mr Paul Wright, the CEO of Universal Biosensors.
Executive Interviews
Why Are Fewer Companies Going Public?
The number of companies listing on the ASX has declined, driven by access to private capital, regulatory burdens, and market volatility. However, public markets still offer liquidity, visibility, and robust capital-raising opportunities.
A Message to Founders: A Shared Journey to 2025 – A Once in a Generation Opportunity
As we close this challenging year, let’s reflect on the resilience, lessons, and growth that brought us here. Founders, 2025 is your golden opportunity to innovate, scale, and thrive. Set your strategy, rest, and prepare to sprint into a year of unparalleled possibilities.
From Trash to Treasure: Inside Australia’s First Commercial Waste-to-Hydrogen Facility
Greenhill Energy’s pioneering waste-to-hydrogen facility marks a significant step in sustainable energy. This Australian innovation is transforming waste management into clean, valuable hydrogen, presenting investors with a unique, forward-thinking opportunity.
Backed By Leading Investment Groups and Family Offices
